Table 1.
Nivolumab content of the nivolumab-PEG-PCL nanoparticles of various PEG-PCL amounts used in the nanoprecipitation process
Ratio of PEG-PCL to Nivolumab, % w/w | Nivolumab Content, % w/wa |
---|---|
20 | 2.5 ± 0.11 |
40 | 3.6 ± 0.08 |
60 | 3.8 ± 0.06 |
80 | 3.7 ± 0.09 |
The SD value is for the mean trastuzumab content (% w/w) obtained from three measurements.